Glycemic control in people with type 2 diabetes
Blood Vessel Formation: BPC-157 promotes the formation of new blood vessels, which improves nutrient and oxygen delivery to damaged tissues (Wang et al., 2021)

Best For Patients who have plateaued on semaglutide or tirzepatide Patients with significant weight to lose (50+ pounds) Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome Patients who want access to the most advanced mechanism currently available Patients with established GLP-1 experience and good tolerance Side Effect Comparison All three medications share a similar side effect profile driven primarily by gastrointestinal effects: Common Side Effects (All Three) Nausea most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level Diarrhea reported by 15 to 25 percent of patients Vomiting reported by 8 to 15 percent Constipation reported by 6 to 12 percent Decreased appetite nearly universal and considered therapeutic Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation

N,N-dimethylphenethylamine is a GRAS flavoring additive that is very common in a variety of foods including cereal and generally safe when uses in low amounts as a flavor but safety has not been established at the high amounts used in supplements
The gastrointestinal side effects common with GLP-1 receptor agonistsincluding nausea, diarrhea, constipation, and abdominal discomfortmay overlap with or potentially exacerbate symptoms related to altered bile flow after cholecystectomy